Alpha2beta1 integrin in cancer development and chemoresistance

Seminars in Cancer Biology

Volumn 35, Issue , 2015, Pages 145-153

  Naci, Dalila ^a,c   Vuori, Kristiina ^b   Aoudjit, Fawzi ^a  

^a LAVAL UNIVERSITY   (Canada)

^b BURNHAM INSTITUTE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Alpha2beta1 integrin; Chemoresistance; Collagen; Hematological malignancies; Metastasis

Indexed keywords

COLLAGEN; VERY LATE ACTIVATION ANTIGEN 2;

ACUTE LYMPHOBLASTIC LEUKEMIA; CANCER CELL; CANCER GROWTH; CANCER RESISTANCE; CANCER STEM CELL; CARCINOGENESIS; CELL INVASION; CELL PROLIFERATION; DISEASE ACTIVITY; HEMATOLOGIC MALIGNANCY; HUMAN; MALIGNANT NEOPLASTIC DISEASE; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; MOLECULAR PATHOLOGY; NONHUMAN; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SOLID TUMOR; T LYMPHOCYTE; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL MOTION; CELL TRANSFORMATION; DISEASE COURSE; DRUG RESISTANCE; EXTRACELLULAR MATRIX; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOPLASMS; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR INVASION;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; COLLAGEN; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; EXTRACELLULAR MATRIX; HUMANS; INTEGRIN ALPHA2BETA1; MOLECULAR TARGETED THERAPY; NEOPLASM INVASIVENESS; NEOPLASMS; NEOPLASTIC STEM CELLS; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION;

EID: 84948709732     PISSN: 1044579X     EISSN: 10963650     Source Type: Journal    
DOI: 10.1016/j.semcancer.2015.08.004     Document Type: Review

References (184)

1. Ginsberg M.H., Partridge A., Shattil S.J. Integrin regulation. Curr. Opin. Cell Biol. 2005, 17:509-516.
2. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
3. Humphries J.D., Byron A., Humphries M.J. Integrin ligands at a glance. J. Cell Sci. 2006, 119:3901-3903.
4. Giancotti F.G., Ruoslahti E. Integrin signaling. Science 1999, 285:1028-1032.
5. Hannigan G.E., McDonald P.C., Walsh M.P., Dedhar S. Integrin-linked kinase: not so 'pseudo' after all. Oncogene 2011, 30:4375-4385.
6. Hu P., Luo B.H. Integrin bi-directional signaling across the plasma membrane. J. Cell Physiol. 2013, 228:306-312.
7. Ivaska J., Heino J. Cooperation between integrins and growth factor receptors in signaling and endocytosis. Annu. Rev. Cell Dev. Biol. 2011, 27:291-320.
8. Turner C.E. Paxillin and focal adhesion signalling. Nat. Cell Biol. 2000, 2:E231-E236.
9. Eke I., Cordes N. Focal adhesion signaling and therapy resistance in cancer. Semin. Cancer Biol. 2015, 31:65-75.
10. Jiang W.G., Sanders A.J., Katoh M., Ungefroren H., Gieseler F., Prince M., et al. Tissue invasion and metastasis: molecular, biological and clinical perspectives. Semin. Cancer Biol. 2015, 10.1016/j. semcancer.2015.03.008.
11. Seguin L., Desgrosellier J.S., Weis S.M., Cheresh D.A. Integrins and cancer: regulators of cancer stemness, metastasis, and drug resistance. Trends Cell Biol. 2015, 25:234-240.
12. Barkan D., El Touny L.H., Michalowski A.M., Smith J.A., Chu I., Davis A.S., et al. Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment. Cancer Res. 2010, 70:5706-5716.
13. Lu P., Weaver V.M., Werb Z. The extracellular matrix: a dynamic niche in cancer progression. J. Cell Biol. 2012, 196:395-406.
14. Mouw J.K., Ou G., Weaver V.M. Extracellular matrix assembly: a multiscale deconstruction. Nat. Rev. Mol. Cell Biol. 2014, 15:771-785.
15. Narunsky L., Oren R., Bochner F., Neeman M. Imaging aspects of the tumor stroma with therapeutic implications. Pharmacol. Ther. 2014, 141:192-208.
16. Heino J. Cellular signaling by collagen-binding integrins. Adv. Exp. Med. Biol. 2014, 819:143-155.
17. White D.J., Puranen S., Johnson M.S., Heino J. The collagen receptor subfamily of the integrins. Int. J. Biochem. Cell Biol. 2004, 36:1405-1410.
18. Barczyk M., Carracedo S., Gullberg D. Integrins. Cell Tissue Res. 2010, 339:269-280.
19. Knight C.G., Morton L.F., Peachey A.R., Tuckwell D.S., Farndale R.W., Barnes M.J. The collagen-binding A-domains of integrins alpha(1)beta(1) and alpha(2)beta(1) recognize the same specific amino acid sequence, GFOGER, in native (triple-helical) collagens. J. Biol. Chem. 2000, 275:35-40.
20. Zhang W.M., Kapyla J., Puranen J.S., Knight C.G., Tiger C.F., Pentikainen O.T., et al. alpha 11beta 1 integrin recognizes the GFOGER sequence in interstitial collagens. J. Biol. Chem. 2003, 278:7270-7277.
21. Lundgren-Akerlund E., Aszodi A. Integrin alpha10beta1: a collagen receptor critical in skeletal development. Adv. Exp. Med. Biol. 2014, 819:61-71.
22. Leitinger B., Hohenester E. Mammalian collagen receptors. Matrix Biol. 2007, 26:146-155.
23. Heino J. The collagen receptor integrins have distinct ligand recognition and signaling functions. Matrix Biol. 2000, 19:319-323.
24. Madamanchi A., Santoro S.A., Zutter M.M. alpha2beta1 Integrin. Adv. Exp. Med. Biol. 2014, 819:41-60.
25. McCall-Culbreath K.D., Zutter M.M. Collagen receptor integrins: rising to the challenge. Curr. Drug Targets 2008, 9:139-149.
26. Gardner H. Integrin alpha1beta1. Adv. Exp. Med. Biol. 2014, 819:21-39.
27. Heino J., Huhtala M., Kapyla J., Johnson M.S. Evolution of collagen-based adhesion systems. Int. J. Biochem. Cell Biol. 2009, 41:341-348.
28. Luo B.H., Carman C.V., Springer T.A. Structural basis of integrin regulation and signaling. Annu. Rev. Immunol. 2007, 25:619-647.
29. Lochter A., Navre M., Werb Z., Bissell M.J. alpha1 and alpha2 integrins mediate invasive activity of mouse mammary carcinoma cells through regulation of stromelysin-1 expression. Mol. Biol. Cell 1999, 10:271-282.
30. Ibaragi S., Shimo T., Hassan N.M., Isowa S., Kurio N., Mandai H., et al. Induction of MMP-13 expression in bone-metastasizing cancer cells by type I collagen through integrin alpha1beta1 and alpha2beta1-p38 MAPK signaling. Anticancer Res. 2011, 31:1307-1313.
31. Ravanti L., Heino J., Lopez-Otin C., Kahari V.M. Induction of collagenase-3 (MMP-13) expression in human skin fibroblasts by three-dimensional collagen is mediated by p38 mitogen-activated protein kinase. J. Biol. Chem. 1999, 274:2446-2455.
32. Burleson K.M., Hansen L.K., Skubitz A.P. Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers. Clin. Exp. Metastasis 2004, 21:685-697.
33. Shield K., Riley C., Quinn M.A., Rice G.E., Ackland M.L., Ahmed N. Alpha2beta1 integrin affects metastatic potential of ovarian carcinoma spheroids by supporting disaggregation and proteolysis. J. Carcinog. 2007, 6:11.
34. Uematsu T., Konishi C., Hoshino D., Han X., Tomari T., Egawa N., et al. Identification of proteins that associate with integrin alpha2 by proteomic analysis in human fibrosarcoma HT-1080 cells. J. Cell Physiol. 2012, 227:3072-3079.
35. Baciu P.C., Suleiman E.A., Deryugina E.I., Strongin A.Y. Membrane type-1 matrix metalloproteinase (MT1-MMP) processing of pro-alphav integrin regulates cross-talk between alphavbeta3 and alpha2beta1 integrins in breast carcinoma cells. Exp. Cell Res. 2003, 291:167-175.
36. Vuoriluoto K., Hognas G., Meller P., Lehti K., Ivaska J. Syndecan-1 and -4 differentially regulate oncogenic K-ras dependent cell invasion into collagen through alpha2beta1 integrin and MT1-MMP. Matrix Biol. 2011, 30:207-217.
37. Bassaganas S., Carvalho S., Dias A.M., Perez-Garay M., Ortiz M.R., Figueras J., et al. Pancreatic cancer cell glycosylation regulates cell adhesion and invasion through the modulation of alpha2beta1 integrin and E-cadherin function. PLoS ONE 2014, 9:e98595.
38. Haidari M., Zhang W., Caivano A., Chen Z., Ganjehei L., Mortazavi A., et al. Integrin alpha2beta1 mediates tyrosine phosphorylation of vascular endothelial cadherin induced by invasive breast cancer cells. J. Biol. Chem. 2012, 287:32981-32992.
39. Koyama H., Raines E.W., Bornfeldt K.E., Roberts J.M., Ross R. Fibrillar collagen inhibits arterial smooth muscle proliferation through regulation of Cdk2 inhibitors. Cell 1996, 87:1069-1078.
40. Xia H., Nho R., Kleidon J., Kahm J., Henke C.A. Polymerized collagen inhibits fibroblast proliferation via a mechanism involving the formation of a beta1 integrin-protein phosphatase 2A-tuberous sclerosis complex 2 complex that suppresses S6K1 activity. J. Biol. Chem. 2008, 283:20350-20360.
41. Henriet P., Zhong Z.D., Brooks P.C., Weinberg K.I., DeClerck Y.A. Contact with fibrillar collagen inhibits melanoma cell proliferation by up-regulating p27KIP1. Proc. Natl. Acad. Sci. U.S.A. 2000, 97:10026-10031.
42. Koohestani F., Braundmeier A.G., Mahdian A., Seo J., Bi J., Nowak R.A. Extracellular matrix collagen alters cell proliferation and cell cycle progression of human uterine leiomyoma smooth muscle cells. PLoS ONE 2013, 8:e75844.
43. Grzesiak J.J., Bouvet M. The alpha2beta1 integrin mediates the malignant phenotype on type I collagen in pancreatic cancer cell lines. Br. J. Cancer. 2006, 94:1311-1319.
44. Ohlund D., Franklin O., Lundberg E., Lundin C., Sund M. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer 2013, 13:154.
45. Honore S., Kovacic H., Pichard V., Briand C., Rognoni J.B. Alpha2beta1-integrin signaling by itself controls G1/S transition in a human adenocarcinoma cell line (Caco-2): implication of NADPH oxidase-dependent production of ROS. Exp. Cell Res. 2003, 285:59-71.
46. Shintani Y., Hollingsworth M.A., Wheelock M.J., Johnson K.R. Collagen I promotes metastasis in pancreatic cancer by activating c-Jun NH(2)-terminal kinase 1 and up-regulating N-cadherin expression. Cancer Res. 2006, 66:11745-11753.
47. Koenig A., Mueller C., Hasel C., Adler G., Menke A. Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. Cancer Res. 2006, 66:4662-4671.
48. Shintani Y., Fukumoto Y., Chaika N., Svoboda R., Wheelock M.J., Johnson K.R. Collagen I-mediated up-regulation of N-cadherin requires cooperative signals from integrins and discoidin domain receptor 1. J. Cell Biol. 2008, 180:1277-1289.
49. Li A., Zhou T., Guo L., Si J. Collagen type I regulates beta-catenin tyrosine phosphorylation and nuclear translocation to promote migration and proliferation of gastric carcinoma cells. Oncol. Rep. 2010, 23:1247-1255.
50. Heerboth S., Housman G., Leary M., Longacre M., Byler S., Lapinska K., et al. EMT and tumor metastasis. Clin. Transl. Med. 2015, 4:6.
51. Steinestel K., Eder S., Schrader A.J., Steinestel J. Clinical significance of epithelial-mesenchymal transition. Clin. Transl. Med. 2014, 3:17.
52. Weis S.M., Cheresh D.A. Tumor angiogenesis: molecular pathways and therapeutic targets. Nat. Med. 2011, 17:1359-1370.
53. Bix G., Castello R., Burrows M., Zoeller J.J., Weech M., Iozzo R.A., et al. Endorepellin in vivo: targeting the tumor vasculature and retarding cancer growth and metabolism. J. Natl. Cancer Inst. 2006, 98:1634-1646.
54. Mammoto T., Jiang A., Jiang E., Panigrahy D., Kieran M.W., Mammoto A. Role of collagen matrix in tumor angiogenesis and glioblastoma multiforme progression. Am. J. Pathol. 2013, 183:1293-1305.
55. Senger D.R., Claffey K.P., Benes J.E., Perruzzi C.A., Sergiou A.P., Detmar M. Angiogenesis promoted by vascular endothelial growth factor: regulation through alpha1beta1 and alpha2beta1 integrins. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:13612-13617.
56. Senger D.R., Perruzzi C.A., Streit M., Koteliansky V.E., de Fougerolles A.R., Detmar M. The alpha(1)beta(1) and alpha(2)beta(1) integrins provide critical support for vascular endothelial growth factor signaling, endothelial cell migration, and tumor angiogenesis. Am. J. Pathol. 2002, 160:195-204.
57. Bix G., Fu J., Gonzalez E.M., Macro L., Barker A., Campbell S., et al. Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin. J. Cell Biol. 2004, 166:97-109.
58. Sweeney S.M., DiLullo G., Slater S.J., Martinez J., Iozzo R.V., Lauer-Fields J.L., et al. Angiogenesis in collagen I requires alpha2beta1 ligation of a GFP*GER sequence and possibly p38 MAPK activation and focal adhesion disassembly. J. Biol. Chem. 2003, 278:30516-30524.
59. Whelan M.C., Senger D.R. Collagen I initiates endothelial cell morphogenesis by inducing actin polymerization through suppression of cyclic AMP and protein kinase A. J. Biol. Chem. 2003, 278:327-334.
60. Funahashi Y., Sugi N.H., Semba T., Yamamoto Y., Hamaoka S., Tsukahara-Tamai N., et al. Sulfonamide derivative, E7820, is a unique angiogenesis inhibitor suppressing an expression of integrin alpha2 subunit on endothelium. Cancer Res. 2002, 62:6116-6123.
61. Ito K., Semba T., Uenaka T., Wakabayashi T., Asada M., Funahashi Y. Enhanced anti-angiogenic effect of E7820 in combination with erlotinib in epidermal growth factor receptor-tyrosine kinase inhibitor-resistant non-small-cell lung cancer xenograft models. Cancer Sci. 2014, 105:1023-1031.
62. Semba T., Funahashi Y., Ono N., Yamamoto Y., Sugi N.H., Asada M., et al. An angiogenesis inhibitor E7820 shows broad-spectrum tumor growth inhibition in a xenograft model: possible value of integrin alpha2 on platelets as a biological marker. Clin. Cancer Res. 2004, 10:1430-1438.
63. Rehn M., Veikkola T., Kukk-Valdre E., Nakamura H., Ilmonen M., Lombardo C., et al. Interaction of endostatin with integrins implicated in angiogenesis. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:1024-1029.
64. Maeshima Y., Sudhakar A., Lively J.C., Ueki K., Kharbanda S., Kahn C.R., et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295:140-143.
65. Woodall B.P., Nystrom A., Iozzo R.A., Eble J.A., Niland S., Krieg T., et al. Integrin alpha2beta1 is the required receptor for endorepellin angiostatic activity. J. Biol. Chem. 2008, 283:2335-2343.
66. Nystrom A., Shaik Z.P., Gullberg D., Krieg T., Eckes B., Zent R., et al. Role of tyrosine phosphatase SHP-1 in the mechanism of endorepellin angiostatic activity. Blood 2009, 114:4897-4906.
67. Goyal A., Pal N., Concannon M., Paul M., Doran M., Poluzzi C., et al. Endorepellin, the angiostatic module of perlecan, interacts with both the alpha2beta1 integrin and vascular endothelial growth factor receptor 2 (VEGFR2): a dual receptor antagonism. J. Biol. Chem. 2011, 286:25947-25962.
68. Poluzzi C., Casulli J., Goyal A., Mercer T.J., Neill T., Iozzo R.V. Endorepellin evokes autophagy in endothelial cells. J. Biol. Chem. 2014, 289:16114-16128.
69. Sabherwal Y., Rothman V.L., Dimitrov S., L'Heureux D.Z., Marcinkiewicz C., Sharma M., et al. Integrin alpha2beta1 mediates the anti-angiogenic and anti-tumor activities of angiocidin, a novel tumor-associated protein. Exp. Cell Res. 2006, 312:2443-2453.
70. Levental K.R., Yu H., Kass L., Lakins J.N., Egeblad M., Erler J.T., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 2009, 139:891-906.
71. White D.E., Kurpios N.A., Zuo D., Hassell J.A., Blaess S., Mueller U., et al. Targeted disruption of beta1-integrin in a transgenic mouse model of human breast cancer reveals an essential role in mammary tumor induction. Cancer Cell. 2004, 6:159-170.
72. Ramirez N.E., Zhang Z., Madamanchi A., Boyd K.L., O'Rear L.D., Nashabi A., et al. The alpha(2)beta(1) integrin is a metastasis suppressor in mouse models and human cancer. J. Clin. Invest. 2011, 121:226-237.
73. Tran T., Barlow B., O'Rear L., Jarvis B., Li Z., Dickeson K., et al. Loss of the alpha2beta1 integrin alters human papilloma virus-induced squamous carcinoma progression in vivo and in vitro. PLoS ONE 2011, 6:e26858.
74. Keely P.J., Fong A.M., Zutter M.M., Santoro S.A. Alteration of collagen-dependent adhesion, motility, and morphogenesis by the expression of antisense alpha 2 integrin mRNA in mammary cells. J. Cell Sci. 1995, 108(Pt 2):595-607.
75. Zutter M.M., Santoro S.A., Staatz W.D., Tsung Y.L. Re-expression of the alpha 2 beta 1 integrin abrogates the malignant phenotype of breast carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:7411-7415.
76. 2+. Int. J. Cancer 2008, 122:2199-2209.
77. Lu J., Zhou S., Siech M., Habisch H., Seufferlein T., Bachem M.G. Pancreatic stellate cells promote hapto-migration of cancer cells through collagen I-mediated signalling pathway. Br. J. Cancer 2014, 110:409-420.
78. Lee C.Y., Marzan D., Lin G., Goodison S., Silletti S. alpha2 Integrin-dependent suppression of pancreatic adenocarcinoma cell invasion involves ectodomain regulation of kallikrein-related peptidase-5. J. Oncol. 2011, 2011:365651.
79. Bouvet M., Yang M., Nardin S., Wang X., Jiang P., Baranov E., et al. Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models. Clin. Exp. Metastasis 2000, 18:213-218.
80. Hall C.L., Dai J., van Golen K.L., Keller E.T., Long M.W. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res. 2006, 66:8648-8654.
81. Sottnik J.L., Daignault-Newton S., Zhang X., Morrissey C., Hussain M.H., Keller E.T., et al. Integrin alpha2beta 1 (alpha2beta1) promotes prostate cancer skeletal metastasis. Clin. Exp. Metastasis 2013, 30:569-578.
82. Hall C.L., Dubyk C.W., Riesenberger T.A., Shein D., Keller E.T., van Golen K.L. Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase. Neoplasia 2008, 10:797-803.
83. Bonkhoff H., Stein U., Remberger K. Differential expression of alpha 6 and alpha 2 very late antigen integrins in the normal, hyperplastic, and neoplastic prostate: simultaneous demonstration of cell surface receptors and their extracellular ligands. Hum. Pathol. 1993, 24:243-248.
84. Ziaee S., Chung L.W. Induction of integrin alpha2 in a highly bone metastatic human prostate cancer cell line: roles of RANKL and AR under three-dimensional suspension culture. Mol. Cancer 2014, 13:208.
85. Dudley D.T., Li X.Y., Hu C.Y., Kleer C.G., Willis A.L., Weiss S.J. A 3D matrix platform for the rapid generation of therapeutic anti-human carcinoma monoclonal antibodies. Proc. Natl. Acad. Sci. U.S.A. 2014, 111:14882-14887.
86. Tabaries S., Dong Z., Annis M.G., Omeroglu A., Pepin F., Ouellet V., et al. Claudin-2 is selectively enriched in and promotes the formation of breast cancer liver metastases through engagement of integrin complexes. Oncogene 2011, 30:1318-1328.
87. Bartolome R.A., Barderas R., Torres S., Fernandez-Acenero M.J., Mendes M., Garcia-Foncillas J., et al. Cadherin-17 interacts with alpha2beta1 integrin to regulate cell proliferation and adhesion in colorectal cancer cells causing liver metastasis. Oncogene 2014, 33:1658-1669.
88. Burnier J.V., Wang N., Michel R.P., Hassanain M., Li S., Lu Y., et al. Type IV collagen-initiated signals provide survival and growth cues required for liver metastasis. Oncogene 2011, 30:3766-3783.
89. Pelillo C., Bergamo A., Mollica H., Bestagno M., Sava G. Colorectal cancer metastases settle in the hepatic microenvironment through alpha5beta1 integrin. J. Cell Biochem. 2015, 10.1002/jcb.25189.
90. Yoshimura K., Meckel K.F., Laird L.S., Chia C.Y., Park J.J., Olino K.L., et al. Integrin alpha2 mediates selective metastasis to the liver. Cancer Res. 2009, 69:7320-7328.
91. Lin M.T., Chang C.C., Lin B.R., Yang H.Y., Chu C.Y., Wu M.H., et al. Elevated expression of Cyr61 enhances peritoneal dissemination of gastric cancer cells through integrin alpha2beta1. J. Biol. Chem. 2007, 282:34594-34604.
92. Matsuoka T., Yashiro M., Nishimura S., Inoue T., Fujihara T., Sawada T., et al. Increased expression of alpha2beta1-integrin in the peritoneal dissemination of human gastric carcinoma. Int. J. Mol. Med. 2000, 5:21-25.
93. Ura H., Denno R., Hirata K., Yamaguchi K., Yasoshima T. Separate functions of alpha2beta1 and alpha3beta1 integrins in the metastatic process of human gastric carcinoma. Surg. Today 1998, 28:1001-1006.
94. Malanchi I., Santamaria-Martinez A., Susanto E., Peng H., Lehr H.A., Delaloye J.F., et al. Interactions between cancer stem cells and their niche govern metastatic colonization. Nature 2012, 481:85-89.
95. Bonneau C., Rouzier R., Geyl C., Cortez A., Castela M., Lis R., et al. Predictive markers of chemoresistance in advanced stages epithelial ovarian carcinoma. Gynecol. Oncol. 2015, 136:112-120.
96. Ghiaur G., Wroblewski M., Loges S. Acute myelogenous leukemia and its microenvironment: a molecular conversation. Semin. Hematol. 2015, 52:200-206.
97. Buchheit C.L., Weigel K.J., Schafer Z.T. Cancer cell survival during detachment from the ECM: multiple barriers to tumour progression. Nat. Rev. Cancer 2014, 14:632-641.
98. Stupack D.G., Cheresh D.A. Get a ligand, get a life: integrins, signaling and cell survival. J. Cell Sci. 2002, 115:3729-3738.
99. Fulda S. Tumor resistance to apoptosis. Int. J. Cancer 2009, 124:511-515.
100. Fulda S., Debatin K.M. Targeting apoptosis pathways in cancer therapy. Curr. Cancer Drug Targets 2004, 4:569-576.
101. Aoudjit F., Vuori K. Integrin signaling in cancer cell survival and chemoresistance. Chemother. Res. Pract. 2012, 2012:283181.
102. Meads M.B., Gatenby R.A., Dalton W.S. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9:665-674.
103. Aoudjit F., Vuori K. Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001, 20:4995-5004.
104. Cohen E., Tendler T., Lu H., Hansen C.K., Kertsman J., Barrios J., et al. Collagen I provides a survival advantage to MD-1483 head and neck squamous cell carcinoma cells through phosphoinositol 3-kinase signaling. Anticancer Res. 2013, 33:379-386.
105. Armstrong T., Packham G., Murphy L.B., Bateman A.C., Conti J.A., Fine D.R., et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. Clin. Cancer Res. 2004, 10:7427-7437.
106. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nat. Med. 1999, 5:662-668.
107. Hodkinson P.S., Elliott T., Wong W.S., Rintoul R.C., Mackinnon A.C., Haslett C., et al. ECM overrides DNA damage-induced cell cycle arrest and apoptosis in small-cell lung cancer cells through beta1 integrin-dependent activation of PI3-kinase. Cell Death Differ. 2006, 13:1776-1788.
108. Buttery R.C., Rintoul R.C., Sethi T. Small cell lung cancer: the importance of the extracellular matrix. Int. J. Biochem. Cell Biol. 2004, 36:1154-1160.
109. Rintoul R.C., Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer. Clin. Sci. (Lond.) 2002, 102:417-424.
110. Oshita F., Kameda Y., Ikehara M., Tanaka G., Yamada K., Nomura I., et al. Increased expression of integrin beta1 is a poor prognostic factor in small-cell lung cancer. Anticancer Res. 2002, 22:1065-1070.
111. Morazzani M., de Carvalho D.D., Kovacic H., Smida-Rezgui S., Briand C., Penel C. Monolayer versus aggregate balance in survival process for EGF-induced apoptosis in A431 carcinoma cells: Implication of ROS-P38 MAPK-integrin alpha2beta1 pathway. Int. J. Cancer 2004, 110:788-799.
112. Dangi-Garimella S., Krantz S.B., Barron M.R., Shields M.A., Heiferman M.J., Grippo P.J., et al. Three-dimensional collagen I promotes gemcitabine resistance in pancreatic cancer through MT1-MMP-mediated expression of HMGA2. Cancer Res. 2011, 71:1019-1028.
113. Dangi-Garimella S., Sahai V., Ebine K., Kumar K., Munshi H.G. Three-dimensional collagen I promotes gemcitabine resistance in vitro in pancreatic cancer cells through HMGA2-dependent histone acetyltransferase expression. PLoS ONE 2013, 8:e64566.
114. Kanda R., Kawahara A., Watari K., Murakami Y., Sonoda K., Maeda M., et al. Erlotinib resistance in lung cancer cells mediated by integrin beta1/Src/Akt-driven bypass signaling. Cancer Res. 2013, 73:6243-6253.
115. Denucci C.C., Mitchell J.S., Shimizu Y. Integrin function in T-cell homing to lymphoid and nonlymphoid sites: getting there and staying there. Crit. Rev. Immunol. 2009, 29:87-109.
116. Dustin M.L., de Fougerolles A.R. Reprogramming T cells: the role of extracellular matrix in coordination of T cell activation and migration. Curr. Opin. Immunol. 2001, 13:286-290.
117. Ray S.J., Franki S.N., Pierce R.H., Dimitrova S., Koteliansky V., Sprague A.G., et al. The collagen binding alpha1beta1 integrin VLA-1 regulates CD8 T cell-mediated immune protection against heterologous influenza infection. Immunity 2004, 20:167-179.
118. Meads M.B., Hazlehurst L.A., Dalton W.S. The bone marrow microenvironment as a tumor sanctuary and contributor to drug resistance. Clin. Cancer Res. 2008, 14:2519-2526.
119. Shain K.H., Dalton W.S. Environmental-mediated drug resistance: a target for multiple myeloma therapy. Expert Rev. Hematol. 2009, 2:649-662.
120. Ivanoff J., Talme T., Sundqvist K.G. The role of chemokines and extracellular matrix components in the migration of T lymphocytes into three-dimensional substrata. Immunology 2005, 114:53-62.
121. Mobley J.L., Ennis E., Shimizu Y. Differential activation-dependent regulation of integrin function in cultured human T-leukemic cell lines. Blood 1994, 83:1039-1050.
122. Chan B.M., Wong J.G., Rao A., Hemler M.E. T cell receptor-dependent, antigen-specific stimulation of a murine T cell clone induces a transient, VLA protein-mediated binding to extracellular matrix. J. Immunol. 1991, 147:398-404.
123. Aoudjit F., Vuori K. Engagement of the alpha2beta1 integrin inhibits Fas ligand expression and activation-induced cell death in T cells in a focal adhesion kinase-dependent manner. Blood 2000, 95:2044-2051.
124. Gendron S., Couture J., Aoudjit F. Integrin alpha2beta1 inhibits Fas-mediated apoptosis in T lymphocytes by protein phosphatase 2A-dependent activation of the MAPK/ERK pathway. J. Biol. Chem. 2003, 278:48633-48643.
125. Naci D., El Azreq M.A., Chetoui N., Lauden L., Sigaux F., Charron D., et al. alpha2beta1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J. Biol. Chem. 2012, 287:17065-17076.
126. Liu C.C., Leclair P., Yap S.Q., Lim C.J. The membrane-proximal KXGFFKR motif of alpha-integrin mediates chemoresistance. Mol. Cell. Biol. 2013, 33:4334-4345.
127. Sugahara H., Kanakura Y., Furitsu T., Ishihara K., Oritani K., Ikeda H., et al. Induction of programmed cell death in human hematopoietic cell lines by fibronectin via its interaction with very late antigen 5. J. Exp. Med. 1994, 179:1757-1766.
128. Damle N.K., Klussman K., Leytze G., Aruffo A., Linsley P.S., Ledbetter J.A. Costimulation with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 augments activation-induced death of antigen-specific CD4+ T lymphocytes. J. Immunol. 1993, 151:2368-2379.
129. Cleaver A.L., Beesley A.H., Firth M.J., Sturges N.C., O'Leary R.A., Hunger S.P., et al. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: a Children's Oncology Group study. Mol. Cancer 2010, 9:105.
130. Shishido S., Bonig H., Kim Y.M. Role of integrin alpha4 in drug resistance of leukemia. Front. Oncol. 2014, 4:99.
131. Shalapour S., Hof J., Kirschner-Schwabe R., Bastian L., Eckert C., Prada J., et al. High VLA-4 expression is associated with adverse outcome and distinct gene expression changes in childhood B-cell precursor acute lymphoblastic leukemia at first relapse. Haematologica 2011, 96:1627-1635.
132. Nuckel H., Switala M., Collins C.H., Sellmann L., Grosse-Wilde H., Duhrsen U., et al. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin. Immunol. 2009, 131:472-480.
133. Hsieh Y.T., Gang E.J., Geng H., Park E., Huantes S., Chudziak D., et al. Integrin alpha4 blockade sensitizes drug resistant pre-B acute lymphoblastic leukemia to chemotherapy. Blood 2013, 121:1814-1818.
134. Matsunaga T., Takemoto N., Sato T., Takimoto R., Tanaka I., Fujimi A., et al. Interaction between leukemic-cell VLA-4 and stromal fibronectin is a decisive factor for minimal residual disease of acute myelogenous leukemia. Nat. Med. 2003, 9:1158-1165.
135. Walter R.B., Alonzo T.A., Gerbing R.B., Ho P.A., Smith F.O., Raimondi S.C., et al. High expression of the very late antigen-4 integrin independently predicts reduced risk of relapse and improved outcome in pediatric acute myeloid leukemia: a report from the children's oncology group. J. Clin. Oncol. 2010, 28:2831-2838.
136. Becker P.S., Kopecky K.J., Wilks A.N., Chien S., Harlan J.M., Willman C.L., et al. Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 2009, 113:866-874.
137. Estrugo D., Fischer A., Hess F., Scherthan H., Belka C., Cordes N. Ligand bound beta1 integrins inhibit procaspase-8 for mediating cell adhesion-mediated drug and radiation resistance in human leukemia cells. PLoS ONE 2007, 2:e269.
138. El Azreq M.A., Naci D., Aoudjit F. Collagen/beta1 integrin signaling up-regulates the ABCC1/MRP-1 transporter in an ERK/MAPK-dependent manner. Mol. Biol. Cell 2012, 23:3473-3484.
139. Morel C., Carlson S.M., White F.M., Davis R.J. Mcl-1 integrates the opposing actions of signaling pathways that mediate survival and apoptosis. Mol. Cell. Biol. 2009, 29:3845-3852.
140. Thomas L.W., Lam C., Edwards S.W. Mcl-1: the molecular regulation of protein function. FEBS Lett. 2010, 584:2981-2989.
141. Deeley R.G., Westlake C., Cole S.P. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol. Rev. 2006, 86:849-899.
142. Kasimir-Bauer S., Ottinger H., Meusers P., Beelen D.W., Brittinger G., Seeber S., et al. In acute myeloid leukemia, coexpression of at least two proteins, including P-glycoprotein, the multidrug resistance-related protein, bcl-2, mutant p53, and heat-shock protein 27, is predictive of the response to induction chemotherapy. Exp. Hematol. 1998, 26:1111-1117.
143. Shaffer B.C., Gillet J.P., Patel C., Baer M.R., Bates S.E., Gottesman M.M. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist. Updat. 2012, 15:62-69.
144. Szakacs G., Hall M.D., Gottesman M.M., Boumendjel A., Kachadourian R., Day B.J., et al. Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem. Rev. 2014, 114:5753-5774.
145. Chetoui N., Gendron S., Chamoux E., Aoudjit F. Collagen type I-mediated activation of ERK/MAP Kinase is dependent on Ras, Raf-1 and protein phosphatase 2A in Jurkat T cells. Mol. Immunol. 2006, 43:1687-1693.
146. Kornblau S.M., Womble M., Qiu Y.H., Jackson C.E., Chen W., Konopleva M., et al. Simultaneous activation of multiple signal transduction pathways confers poor prognosis in acute myelogenous leukemia. Blood 2006, 108:2358-2365.
147. Winter S.S., Ricci J., Luo L., Lovato D.M., Khawaja H.M., Serna-Gallegos T., et al. ATP Binding Cassette C1 (ABCC1/MRP1)-mediated drug efflux contributes to disease progression in T-lineage acute lymphoblastic leukemia. Health (Irvine Calif.) 2013, 5.
148. Plasschaert S.L., de Bont E.S., Boezen M., vander Kolk D.M., Daenen S.M., Faber K.N., et al. Expression of multidrug resistance-associated proteins predicts prognosis in childhood and adult acute lymphoblastic leukemia. Clin. Cancer Res. 2005, 11:8661-8668.
149. Holleman A., Cheok M.H., den Boer M.L., Yang W., Veerman A.J., Kazemier K.M., et al. Gene-expression patterns in drug-resistant acute lymphoblastic leukemia cells and response to treatment. N. Engl. J. Med. 2004, 351:533-542.
150. Kaufmann S.H., Karp J.E., Svingen P.A., Krajewski S., Burke P.J., Gore S.D., et al. Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. Blood 1998, 91:991-1000.
151. Loriaux M.M., Levine R.L., Tyner J.W., Frohling S., Scholl C., Stoffregen E.P., et al. High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia. Blood 2008, 111:4788-4796.
152. Steelman L.S., Franklin R.A., Abrams S.L., Chappell W., Kempf C.R., Basecke J., et al. Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. Leukemia 2011, 25:1080-1094.
153. Bose P., Grant S. Mcl-1 as a therapeutic target in acute myelogenous leukemia (AML). Leuk. Res. Rep. 2013, 2:12-14.
154. Naci D., Aoudjit F. Alpha2beta1 integrin promotes T cell survival and migration through the concomitant activation of ERK/Mcl-1 and p38 MAPK pathways. Cell Signal. 2014, 26:2008-2015.
155. Kreso A., Dick J.E. Evolution of the cancer stem cell model. Cell Stem. Cell. 2014, 14:275-291.
156. Islam F., Gopalan V., Smith R.A., Lam A.K. Translational potential of cancer stem cells: a review of the detection of cancer stem cells and their roles in cancer recurrence and cancer treatment. Exp. Cell Res. 2015, 335:135-147.
157. Ellis S.J., Tanentzapf G. Integrin-mediated adhesion and stem-cell-niche interactions. Cell Tissue Res. 2010, 339:121-130.
158. Farahani E., Patra H.K., Jangamreddy J.R., Rashedi I., Kawalec M., Rao Pariti R.K., et al. Cell adhesion molecules and their relation to (cancer) cell stemness. Carcinogenesis 2014, 35:747-759.
159. Li H.Y., Liao C.Y., Lee K.H., Chang H.C., Chen Y.J., Chao K.C., et al. Collagen IV significantly enhances migration and transplantation of embryonic stem cells: involvement of alpha2beta1 integrin-mediated actin remodeling. Cell Transpl. 2011, 20:893-907.
160. Suh H.N., Han H.J. Collagen I regulates the self-renewal of mouse embryonic stem cells through alpha2beta1 integrin- and DDR1-dependent Bmi-1. J. Cell Physiol. 2011, 226:3422-3432.
161. Roy V., Verfaillie C.M. Expression and function of cell adhesion molecules on fetal liver, cord blood and bone marrow hematopoietic progenitors: implications for anatomical localization and developmental stage specific regulation of hematopoiesis. Exp. Hematol. 1999, 27:302-312.
162. Oswald J., Steudel C., Salchert K., Joergensen B., Thiede C., Ehninger G., et al. Gene-expression profiling of CD34+ hematopoietic cells expanded in a collagen I matrix. Stem Cells 2006, 24:494-500.
163. Wong W.M., Sigvardsson M., Astrand-Grundstrom I., Hogge D., Larsson J., Qian H., et al. Expression of integrin alpha2 receptor in human cord blood CD34+CD38-CD90+ stem cells engrafting long-term in NOD/SCID-IL2Rgamma(c) null mice. Stem Cells 2013, 31:360-371.
164. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 2006, 12:1167-1174.
165. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 2011, 11:254-267.
166. Finones R.R., Yeargin J., Lee M., Kaur A.P., Cheng C., Sun P., et al. Early human prostate adenocarcinomas harbor androgen-independent cancer cells. PLoS ONE 2013, 8:e74438.
167. Patrawala L., Calhoun-Davis T., Schneider-Broussard R., Tang D.G. Hierarchical organization of prostate cancer cells in xenograft tumors: the CD44+ alpha2beta1+ cell population is enriched in tumor-initiating cells. Cancer Res. 2007, 67:6796-6805.
168. Eaton C.L., Colombel M., van der Pluijm G., Cecchini M., Wetterwald A., Lippitt J., et al. Evaluation of the frequency of putative prostate cancer stem cells in primary and metastatic prostate cancer. Prostate 2010, 70:875-882.
169. Trerotola M., Rathore S., Goel H.L., Li J., Alberti S., Piantelli M., et al. CD133, Trop-2 and alpha2beta1 integrin surface receptors as markers of putative human prostate cancer stem cells. Am. J. Transl. Res. 2010, 2:135-144.
170. Bansal N., Davis S., Tereshchenko I., Budak-Alpdogan T., Zhong H., Stein M.N., et al. Enrichment of human prostate cancer cells with tumor initiating properties in mouse and zebrafish xenografts by differential adhesion. Prostate 2014, 74:187-200.
171. Salaam A.D., Hwang P., McIntosh R., Green H.N., Jun H.W., Dean D. Nanodiamond-DGEA peptide conjugates for enhanced delivery of doxorubicin to prostate cancer. Beilstein J. Nanotechnol. 2014, 5:937-945.
172. Kirkland S.C., Ying H. Alpha2beta1 integrin regulates lineage commitment in multipotent human colorectal cancer cells. J. Biol. Chem. 2008, 283:27612-27619.
173. Kirkland S.C. Type I collagen inhibits differentiation and promotes a stem cell-like phenotype in human colorectal carcinoma cells. Br. J. Cancer 2009, 101:320-326.
174. Chen J., Diacovo T.G., Grenache D.G., Santoro S.A., Zutter M.M. The alpha(2) integrin subunit-deficient mouse: a multifaceted phenotype including defects of branching morphogenesis and hemostasis. Am. J. Pathol. 2002, 161:337-344.
175. Holtkotter O., Nieswandt B., Smyth N., Muller W., Hafner M., Schulte V., et al. Integrin alpha 2-deficient mice develop normally, are fertile, but display partially defective platelet interaction with collagen. J. Biol. Chem. 2002, 277:10789-10794.
176. El Azreq M.A., Boisvert M., Cesaro A., Page N., Loubaki L., Allaeys I., et al. alpha2beta1 integrin regulates Th17 cell activity and its neutralization decreases the severity of collagen-induced arthritis. J. Immunol. 2013, 191:5941-5950.
177. Nissinen L., Ojala M., Langen B., Dost R., Pihlavisto M., Kapyla J., et al. Sulfonamide inhibitors of alpha2beta1 integrin reveal the essential role of collagen receptors in in vivo models of inflammation. Pharmacol. Res. Perspect. 2015, 3:e00146.
178. Kassiotis G., Gray D., Kiafard Z., Zwirner J., Stockinger B. Functional specialization of memory Th cells revealed by expression of integrin CD49b. J. Immunol. 2006, 177:968-975.
179. Mita M., Kelly K.R., Mita A., Ricart A.D., Romero O., Tolcher A., et al. Phase I study of E7820, an oral inhibitor of integrin alpha-2 expression with antiangiogenic properties, in patients with advanced malignancies. Clin. Cancer Res. 2011, 17:193-200.
180. Keizer R.J., Funahashi Y., Semba T., Wanders J., Beijnen J.H., Schellens J.H., et al. Evaluation of alpha2-integrin expression as a biomarker for tumor growth inhibition for the investigational integrin inhibitor E7820 in preclinical and clinical studies. Aaps J. 2011, 13:230-239.
181. T.G. Kapp, F. Rechenmacher, T.R. Sobahi, Kessler H. Integrin modulators: a patent review, Expert Opin. Ther. Pat. 23 (2013) 1273-1295.
182. Goodman S.L., Picard M. Integrins as therapeutic targets. Trends Pharmacol. Sci. 2012, 33:405-412.
183. Attinger A., Hou S., Pesenti E., Mancini L., Mottl H. GBR 500, a monoclonal VLA-2 antibody inhibits tumor and metastasis growth but not extravasation in a prostate cancer animal model. Cancer Res. 2011, 71(8 (Suppl.)). (abstract: LB-294).
184. Hou S., Mancini L., Pesenti E., Mottl H. Antitumor activity of GBR 500, a monoclonal VLA-2 antibody. Mol. Cancer Ther. 2011, 10. 11 (abstract: C64).